[5], [8], [9]. It has also been demonstrated that, beyond roles in carcinogenesis, Bcl-2 can activate anti-apoptotic cellular defense of lung cancer cells to therapeutic treatments, such as cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies, which may affect the prognosis of lung cancer patients [10]. Various single-nucleotide polymorphisms (SNP) in apoptotic genes have been demonstrated to contribute to lung cancer [11]–[13], but data is scare on the associations of BCL2 variants with lung cancer risk and prognosis. Here, BCL2 is linked to lung carcinoma.